Children with sickle cell anemia and APOL1 genetic variants develop albuminuria early in life


Disclosures: M.J.W receives consulting payments from Beam Therapeutics, GlaxoSmithKline, and Novartis. As a consultant, he received stock options form Beam Therapeutics and Rubius Inc. J.S.H is a consultant for bluebird bio and Global Blood Therapeutics Research Support, and receives research support from Novartis. J.H.E receives funding support from Pfizer and Eli Lilly and Co and serves as a consultant for Daiichi Sankyo and Global Blood Therapeutics. J.D.L receives funding for the NHLBI and Pfizer to support his research and serves as a consultant to Novartis. The other authors declare no competing financial interests.

Contributions: R.S.Z designed the research and wrote the manuscript. E.R analyzed the data and wrote methods/results sections. G.K analyzed the data and editing methods/results. M.J.W participated in planning the study and provided review/edits. G.W. analyzed genomic data included. R.L.D provided review and edits. J.S.H and J.H.E designed the research and provided guidance on methods and interpretation, review and edits. J.L designed the research, provided guidance on methods and interpretation, wrote the manuscript, and provided review and edits.